Field Note on Central Venous Pressure (CVP) ICU Progress Note

Service: Critical Care / ICU

Subjective:
Patient seen and assessed this morning. Limited participation due to medical condition but responsive to verbal stimuli. No acute distress observed. Daughter present at bedside and reports patient appears more tired and sleepy but without new neurological changes.

Objective:

• General: Frail, elderly female; mildly irritable with examination.

• Neuro: AAOx0, moves left side freely, right side weaker but with preserved grip strength. No acute deterioration noted.

• Respiratory: On room air, decreased air entry bilaterally; no rales, rhonchi, or wheezing.

• Cardiac: Irregular rhythm (known atrial fibrillation), S1/S2 present, no murmurs, gallops, or rubs.

• Abdomen: Soft, non-tender, non-distended; bowel sounds normoactive.

• Extremities: Mild–moderate bilateral pitting edema.

• Skin: Warm and dry.

• Lines: Central venous catheter in place for monitoring and heparin infusion.

• VSS: 

• CVP: 10

Laboratory / Monitoring:

• Central venous pressure monitored via central line.

• Heparin infusion ongoing—APTT and platelet monitoring per protocol.

• All oral medications currently held due to hemodynamic instability and altered mentation.

• No evidence of active infection on current labs; ceftriaxone continued.

Assessment:
83-year-old female with multiple comorbidities, currently on IV antibiotics and anticoagulation, with polypharmacy minimized to essential therapies.
CVP measurement in use to assist with hemodynamic evaluation.

Teaching Point – CVP Interpretation:
Central Venous Pressure reflects right atrial pressure, but does not reliably predict intravascular volume or fluid responsiveness.

• Low CVP does not always indicate hypovolemia, and high CVP does not necessarily indicate fluid overload.

• Studies show no consistent correlation between CVP and blood volume or cardiac output.

• Higher CVP (>12 mmHg) has been linked to worse outcomes in septic and critically ill patients, including increased risk of AKI and mortality.

• The clinical goal is not to normalize CVP, but to maintain adequate perfusion and oxygen delivery to tissues.

• Always interpret CVP in context with other hemodynamic parameters (MAP, urine output, lactate, cardiac output, clinical perfusion).

Plan:

1. Continue Heparin infusion – monitor APTT and signs of bleeding; oral anticoagulants held.

2. Continue Ceftriaxone 1 g IV daily for empiric coverage.

3. Fluid management:

   • Avoid aggressive fluid resuscitation; maintain euvolemia.

   • Use CVP trends only as supportive data, not sole decision criteria.

4. Renal function: monitor urine output and creatinine closely given elevated CVP and risk for congestion-related AKI.

5. Cardiac monitoring: continue telemetry for rhythm control; avoid beta-blockers or calcium channel blockers while hemodynamically unstable.

6. Nutrition: reassess ability for oral intake; continue IV fluids as indicated.

7. Review of medications: all held oral agents to be reintroduced gradually once patient is stable and responsive.

8. Family communication: continue updates and shared decision-making.

Summary:
Patient remains hemodynamically monitored and clinically stable on heparin and IV antibiotics. No acute distress. Current management focuses on maintaining organ perfusion, preventing volume overload, and minimizing iatrogenic harm.
Care plan reviewed and revised; discussed with ICU team and family at bedside.